Nuzenio

Commercialise Senaparib Across

Commercialise Senaparib Across news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 6 latest news signals 6 publisher sources 100/100 entity strength

Latest news

IMPACT Therapeutics grants Pharmanovia exclusive $488m rights to senaparib - Pharmaceutical TechnologyPharmaceutical Technology · Mon, 03 Aug 2026 11:22:18 GMTPharmanovia to pay IMPACT over €420M for certain rights to oral PARP1/2 inhibitor senaparib - FirstWord PharmaFirstWord Pharma · Fri, 31 Jul 2026 15:36:36 GMTIMPACT Therapeutics, Inc and Pharmanovia Enter Exclusive License Agreement For Senaparib In Europe, Middle East And North Africa, Australia And New Zealand - marketscreener.commarketscreener.com · Fri, 31 Jul 2026 10:50:46 GMTIMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand - The Manila TimesThe Manila Times · Fri, 31 Jul 2026 08:06:11 GMTPharmanovia licenses China-approved PARP drug for up to €423.5M - European Biotechnology MagazineEuropean Biotechnology Magazine · Fri, 31 Jul 2026 07:00:00 GMTEupraxia Pharma Partners with Pharmanovia to License Senaparib in 66 Countries Including EU; Shares Surge Over 12% - finance.biggo.comfinance.biggo.com · Thu, 30 Jul 2026 07:00:00 GMT

Timeline

Mon, 03 Aug 2026 11:22:18 GMTIMPACT Therapeutics grants Pharmanovia exclusive $488m rights to senaparib - Pharmaceutical Technology
Fri, 31 Jul 2026 15:36:36 GMTPharmanovia to pay IMPACT over €420M for certain rights to oral PARP1/2 inhibitor senaparib - FirstWord Pharma
Fri, 31 Jul 2026 10:50:46 GMTIMPACT Therapeutics, Inc and Pharmanovia Enter Exclusive License Agreement For Senaparib In Europe, Middle East And North Africa, Australia And New Zealand - marketscreener.com
Fri, 31 Jul 2026 08:06:11 GMTIMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand - The Manila Times
Fri, 31 Jul 2026 07:00:00 GMTPharmanovia licenses China-approved PARP drug for up to €423.5M - European Biotechnology Magazine
Thu, 30 Jul 2026 07:00:00 GMTEupraxia Pharma Partners with Pharmanovia to License Senaparib in 66 Countries Including EU; Shares Surge Over 12% - finance.biggo.com

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Commercialise Senaparib Across.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

6 distinct publisher/source names are currently connected to this entity page.